| Drug Name |
Epoprostenol sodium |
| Drug ID |
BADD_D00789 |
| Description |
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. |
| Indications and Usage |
For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy. |
| Marketing Status |
approved |
| ATC Code |
B01AC09 |
| DrugBank ID |
DB01240
|
| KEGG ID |
D01337
|
| MeSH ID |
D011464
|
| PubChem ID |
6364626
|
| TTD Drug ID |
D0V0IX
|
| NDC Product Code |
14474-025; 54893-0004; 82231-106; 0173-0517; 0009-5164; 0173-0519; 61556-030; 68245-0005 |
| UNII |
4K04IQ1OF4
|
| Synonyms |
Epoprostenol | Epoprostanol | Prostaglandin I2 | Prostacyclin | Prostaglandin I(2) | Veletri | Epoprostenol Sodium | Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer | Flolan |
